Researchers have made a significant advancement in understanding Alzheimer's disease with the identification of a new trigger and an innovative drug, known as Compound 10. This discovery is the culmination of nearly two decades of dedicated research led by Ursula Quitterer, a Professor of Molecular Pharmacology at ETH Zurich.
Long-Term Investigation into Alzheimer's
The journey began almost 20 years ago when Quitterer received brain tissue samples from Ain Shams University Hospital in Cairo. These samples, collected during tumor surgeries, were sourced from both dementia patients and healthy individuals.
These invaluable samples initiated a focused study on a protein named GRK2, which has been central to Quitterer's research endeavors. GRK2 is essential for cellular regulation, aiding cells in responding to signals and managing stress, particularly in the heart and brain where it promotes healthy nerve cell function.
Utilizing human brain tissue and mouse models, the ETH Zurich team discovered that GRK2 might play a pivotal role in the mechanisms of dementia. Their findings have been recently published in the journal Cell Reports Medicine.
The Dual Nature of GRK2
GRK2 exists in two forms within cells: one that functions normally and another that becomes inactive through cellular processes. The research team observed that the inactive form accumulates significantly in the brains of dementia patients, and similar patterns were noted in mice exhibiting Alzheimer's-like symptoms.
Inactive GRK2 aggregates form within nerve cells, attaching to mitochondria and disrupting their vital functions. "These aggregates block mitochondrial pores, reducing energy supply and inducing stress within the cells," explains Quitterer.
Moreover, inactive GRK2 seems to enhance the production of amyloid beta, a protein fragment closely linked to Alzheimer's, creating a detrimental cycle that exacerbates the disease.
Breaking the Cycle with Compound 10
In an effort to disrupt this harmful cycle, the research team developed several experimental compounds, with Compound 10 showing remarkable efficacy. This compound effectively prevented the aggregation of GRK2, thereby allowing mitochondria to function optimally. Consequently, levels of amyloid beta decreased, promoting healthier nerve cells and slowing cell death.
Interestingly, the benefits of Compound 10 extended beyond neurological health, also appearing to enhance heart function and even influence aging-related changes in mice.
Challenges in Alzheimer's Research
The lengthy duration of this research can be attributed to the complexities inherent in Alzheimer's studies. Working with older mice, typically aged between one and two years, necessitated extended periods for meaningful results to emerge.
ETH Zurich has now filed a patent for Compound 10 and is actively seeking partnerships to advance its development into a viable drug. Quitterer emphasizes the importance of this breakthrough: "Identifying GRK2 as a new target protein, along with an active ingredient that works through a different mechanism than existing Alzheimer's drugs, could pave the way for innovative treatment strategies."
While further research is essential before human trials can commence, this discovery heralds a promising direction in the quest for effective Alzheimer's therapies, potentially enhancing patient quality of life in the future.